Rexetin

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Rexetin

Quick Facts

Property Description
Active Ingredient Paroxetine hydrochloride
Form Tablet (Immediate and Controlled-Release), Oral Suspension
Pharmacological Class Selective Serotonin Reuptake Inhibitor (SSRI)
General Purpose Stabilization of mood and emotional state
Origin Synthetic compound

Rexetin: What Type of Medicine is Paroxetine?

Rexetin is a prescription-only psychotropic drug whose active constituent is Paroxetine hydrochloride, officially categorized as a Selective Serotonin Reuptake Inhibitor (SSRI). Paroxetine is assigned the Anatomical Therapeutic Chemical (ATC) code N06AB05 for antidepressants. This designation confirms its role as an agent used for modulating brain chemistry. As a chemically synthesized compound, Paroxetine is recognized in pharmacological studies for being a particularly potent and highly selective inhibitor of serotonin reuptake. This characteristic potency allows for a focused therapeutic effect compared to less selective agents.

Composition, Forms, and General Purpose

The drug is manufactured as a single-ingredient product for oral administration, typically available as a tablet or an oral suspension. The existence of both standard immediate-release and controlled-release (extended-release) variants is a key feature of Paroxetine formulations. The controlled-release system is designed to manage consistency by gradually delivering the active substance, Paroxetine, over an extended period. The core mechanism principle involves the inhibition of neuronal reuptake of serotonin by blocking the serotonin reuptake transporter (SERT), thereby enhancing serotonergic activity. This action helps restore neurochemical balance to stabilize mood and relieve persistent feelings of sadness, offering general support for emotional regulation.

Regulatory References

  1. WHO Essential Medicines List for Anxiety Disorders (Paroxetine included)

What side effects are possible with Rexetin?

Possible Side Effects and Safety Information

The official safety profile of Rexetin (Paroxetine) is documented through regulatory channels like the FDA and EMA, classifying adverse reactions by frequency and physiological system.

Classification Examples of Officially Documented Effects
Very Common Nausea, certain forms of Sexual Dysfunction (e.g., ejaculation failure, decreased libido).
Common Somnolence, Dizziness, Insomnia, Tremor, Dry Mouth, Constipation, Sweating, Asthenia, Weight increase.
System-Organ Classes Effects are grouped into categories like Gastrointestinal Disorders, Nervous System Disorders, Psychiatric Disorders, and Eye Disorders (e.g., blurred vision).

Serious adverse reactions are explicitly noted in the regulatory documents due to their clinical significance. These include the risk of Serotonin Syndrome (a potentially life-threatening reaction), clinically significant Abnormal Bleeding (including gastrointestinal), Seizures, and Acute Narrow-Angle Glaucoma.

Time-Related Safety Patterns

The risk of Suicidal Thoughts and Behavior is heightened in children, adolescents, and young adults (up to age 24) during the initial phase of treatment or following dose changes, as specified in regulatory warnings. Abrupt discontinuation of the medicine is associated with a Discontinuation Syndrome.

Population-Specific Safety

Specific safety considerations are defined for certain groups: Older Adults have a documented increased risk of Hyponatraemia (low sodium) and bleeding. Patients with Hepatic or Severe Renal Impairment may require a reduced maximum daily dose. Official labels also note that exposure during the first trimester of pregnancy may be associated with an increased risk of specific cardiovascular malformations.

Safety Restrictions

Absolute contraindications prohibit the use of Paroxetine with Monoamine Oxidase Inhibitors (MAOIs), or within 14 days of discontinuing an MAOI, due to the high risk of Serotonin Syndrome. Co-administration with certain drugs, such as Pimozide and Thioridazine, is also strictly restricted in the official labeling.

Overdose and Emergency Response

Overdose and when to seek help

A Paroxetine overdose can lead to severe and potentially life-threatening clinical manifestations. Immediate medical attention must be sought if an overdose is suspected or if symptoms of acute toxicity emerge. Urgent care is required due to the risk of life-threatening complications such as Serotonin Syndrome, seizures, and significant cardiac effects.


Documented overdose presentations include central nervous system (CNS) effects such as confusion, agitation, and potentially seizures or coma. Autonomic instability is frequently observed, manifesting as hyperthermia, tachycardia, diaphoresis (sweating), and fluctuating blood pressure. Neuromuscular aberrations like hyperreflexia, myoclonus, and rigidity are also officially recorded. The most serious outcome documented is Serotonin Syndrome, which requires the immediate discontinuation of Rexetin and any other serotonergic medications.


Management is strictly limited to symptomatic and supportive treatment, as no specific antidote is known. Procedures like gastric lavage and continuous cardiovascular monitoring are necessary. Regulatory documentation notes specific population risks: elderly patients are at an increased risk of hyponatraemia (low sodium), and individuals with severe hepatic or renal impairment may experience higher plasma concentrations, increasing the risk of toxicity upon overdose.

Therapeutic Uses of Rexetin

Rexetin (Paroxetine) is a prescription medicine commonly used to manage several conditions where symptoms create noticeable interference with daily stability. The active component of Rexetin is relevant across multiple therapeutic domains where short-term symptom management is appropriate.

This medication is applied across several therapeutic areas where supportive symptom management is appropriate, including Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Panic Disorder, Generalized Anxiety Disorder (GAD), and Posttraumatic Stress Disorder (PTSD). It is also used in specific conditions marked by episodic or fluctuating symptom patterns, such as Premenstrual Dysphoric Disorder (PMDD) and moderate-to-severe vasomotor symptoms associated with menopause.

In situations where patients experience these challenging manifestations, Rexetin helps address symptom clusters that may become intense or disruptive. The medication is applied in scenarios where additional management of discomfort is required.

“The therapeutic use of this medication is primarily to assist with symptoms that interfere with daily functioning when emotional or physical manifestations become more noticeable.”


Quick Fact: Relief for Heightened Symptoms

Category Symptom Management Role
Mood Supports patients during difficult episodes by easing distress related to persistent sadness.
Anxiety Contributes to easing the overall symptom load related to fear and worry.
Specialized May assist with managing symptoms associated with acute or episodic changes.

Regulatory References

  1. U.S. National Library of Medicine (DailyMed) on Paroxetine

Eligibility and Restrictions for Use

Rexetin, which contains the active substance paroxetine, is subject to specific regulatory eligibility and non-eligibility rules established by government health authorities. Use is strictly limited to certain populations, with several groups formally excluded or requiring close restriction.

Contraindicated Populations

Use of this medicine is strictly prohibited in patients with a known hypersensitivity to paroxetine or any of its ingredients. It is also contraindicated in patients taking or who have recently stopped taking Monoamine Oxidase Inhibitors (MAOIs), including linezolid and intravenous methylene blue, due to the risk of a serious adverse event. Concomitant use with pimozide or thioridazine is also prohibited.

Age- and Condition-Based Restrictions

Population Group Eligibility Status
Children and Adolescents (Under 18) Not approved for most psychiatric conditions; use is not recommended due to lack of established efficacy and increased risk of suicidal thoughts and behaviors.
Pregnant Females Not generally recommended, particularly during the first trimester, due to a small, increased risk of cardiovascular malformations in the fetus. Use requires careful risk-benefit assessment.
Breastfeeding Females Generally cautioned against or requires medical discretion, as the drug passes into breast milk and has been associated with harmful effects in some infants.
Severe Renal/Hepatic Impairment Requires a reduced starting dose and cautious use due to increased drug concentrations in the body.
Patients on Tamoxifen Use is restricted/cautioned as paroxetine may reduce Tamoxifen's effectiveness.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Rexetin (Paroxetine) has an official interaction profile defined by both pharmacokinetic and pharmacodynamic mechanisms, resulting in specific regulatory restrictions. The primary pharmacokinetic constraint involves Paroxetine's role as a potent inhibitor of the CYP2D6 enzyme, which is documented to significantly increase the plasma concentrations of co-administered medicines that are substrates of this enzyme. This effect necessitates careful consideration for drugs like Procyclidine and certain tricyclic antidepressants.

Key pharmacodynamic interactions center on the Serotonin System and haemorrhagic risk. The co-administration with other Serotonergic Medicinal Products (e.g., Triptans, Tramadol, Lithium) carries an increased risk of Serotonin Syndrome. Furthermore, official labeling notes an increased haemorrhagic risk when Paroxetine is used with NSAIDs, Aspirin, or Oral Anticoagulants.

Interaction-Related Restrictions

Classification Interacting Substance Restriction / Outcome
Contraindicated MAOIs, Pimozide, Thioridazine Formal prohibition of co-administration.
Timing Rule MAOIs Mandatory 14-day washout period required when switching.
Substance Caution Alcohol, St. John's Wort Official guidance advises avoidance due to increased side effect risk or serotonergic potential.

In populations with severe renal or hepatic impairment, increased plasma concentrations of Paroxetine itself are documented, altering the pharmacokinetic profile and potentially heightening the risk or severity of all drug-drug interactions.

Mechanism of Action

Targeted Inhibition of Serotonin Recycling

This medication primarily acts by engaging the serotonin transporter (SERT) protein on nerve cells, which is responsible for the reuptake (recycling) of serotonin (5-HT). The drug functions as a selective reuptake inhibitor, temporarily blocking the SERT protein from carrying 5-HT back into the presynaptic neuron. This action immediately increases the concentration and duration of the serotonergic signal in the synaptic cleft, initiating the process of altering chemical signal dynamics between neurons.

Modulating Serotonergic Signaling Pathways

Sustained elevation of available serotonin leads to a gradual biological adaptation within neural circuits. Over time, this causes changes in the sensitivity and expression of postsynaptic serotonin receptors. This long-term adjustment contributes to an altered steady-state function of serotonergic signaling within central nervous system pathways that influence complex neural processes. This mechanistic action leads to physiological adjustments that induce an adapted function and modified reactivity within the targeted neural systems.

Dosage and Administration Information

How to Use Rexetin (Paroxetine) — Administration Guidelines

The use of Rexetin is defined by specific procedural guidelines across its approved oral forms, including immediate-release (IR) tablets, controlled-release (CR) tablets, oral suspension, and a specific 7.5 mg capsule. The approved delivery method for all forms is the oral route.

Administration Protocol

Feature Guideline
Dosing Schedule Administered once daily with the dosage gradually adjusted (titrated) over time. Upward adjustments are typically made at intervals of at least one week, starting from a low initial dose specific to the condition.
Timing & Food The medication is generally taken in the morning for most psychiatric indications, or at bedtime for the 7.5 mg capsule. It may be taken with or without food, although it is sometimes recommended to be taken with food for IR tablets.
Special Handling CR tablets must be swallowed whole and must not be chewed, crushed, or split, as this alters the controlled-release mechanism. The oral suspension requires shaking well before measuring a dose.
Missed Dose If a scheduled dose is missed, the next dose should be taken at the usual time; the dose should not be doubled to compensate.

Population & Course Instructions

A reduced initial dose (e.g., 10 mg IR or 12.5 mg CR) and a restricted maximum dose are required for older adults and those with severe hepatic or renal impairment due to altered drug clearance. Treatment duration often extends for many months for chronic conditions. Discontinuation must be gradual, involving a slow reduction of the daily quantity over a period of weeks to avoid abrupt changes.

Recent Clinical Evidence

Research Evidence Overview for Rexetin (Paroxetine)

The available information about Rexetin (Paroxetine) was studied in numerous short-term, randomized controlled trials (RCTs) and comprehensive systematic reviews. These studies, which often compared the drug to an inactive substance (placebo), were used in research exploring how symptoms change over time for various conditions. Research describes group patterns, but study results reflect the specific conditions under which they were conducted and do not determine whether an individual will respond similarly.


Evidence for Use in Major Depressive Disorder and Anxiety Disorders

Research into Major Depressive Disorder has often involved meta-analyses that integrate data from many acute-phase RCTs. These studies monitored outcomes related to systemic or functional imbalance. The research cohorts monitored registered measurements of average symptom scores compared to the placebo cohorts. However, on one particular measure of overall acceptability, a comprehensive analysis reported that the cohorts monitored registered similar measurements compared to the placebo cohort.

For Panic Disorder and Posttraumatic Stress Disorder (PTSD), short-term trials explored whether cohorts receiving Paroxetine showed differences in outcomes related to episodic or acute changes in attack frequency, severity, and symptom measurement across all symptom clusters.


Evidence for Specialized and Episodic Conditions

Research exploring Obsessive-Compulsive Disorder (OCD) has utilized short-term placebo-controlled trials, often lasting 10 to 12 weeks, reporting how symptoms evolved in the observed adult populations. Evidence is limited in terms of characterizing a full, sustained minimal symptom state for many patients after the acute treatment phase.

For Premenstrual Dysphoric Disorder (PMDD), controlled trials evaluated continuous or intermittent dosing, with findings indicating patterns where the Paroxetine cohort showed differences in measured mood symptom scores compared to the placebo cohort. For moderate-to-severe vasomotor symptoms (hot flashes), scientific reviews report that the findings associated with measured VMS frequency and severity were studied in a research context.


Long-Term Studies and Research Gaps

Long-term placebo-controlled discontinuation trials explored maintenance. For certain conditions like depression, long-term studies monitored recurrence and reported patterns where the rate of recurrence was different in the continued Paroxetine cohort compared to the placebo cohort. However, follow-up durations for many other indications remain limited.

Studies primarily focused on adult populations. Regulatory reviews note that the evidence quality for the pediatric population varies, and some findings for older adults suggest a different response profile. Evidence for research exploring head-to-head outcomes against all other available active treatments is lacking.

Frequently Asked Questions (FAQ)

Common questions about Rexetin (FAQ)


Q: What is Rexetin actually prescribed for?

Official documents state that Rexetin is approved for use in conditions including Major Depressive Disorder, various anxiety disorders, Obsessive-Compulsive Disorder (OCD), and Premenstrual Dysphoric Disorder (PMDD). It is also approved for the treatment of moderate-to-severe vasomotor symptoms (hot flashes) associated with menopause. These indications are based on official regulatory approvals.


Q: What are the major warnings listed by the FDA for Rexetin?

According to official regulatory documents, a key warning concerns the risk of increased suicidal thoughts and behavior. This risk is heightened in children, adolescents, and young adults (up to age 24). The warning primarily applies during the initial phase of treatment or following changes in dosage.


Q: What is 'serotonin syndrome' and is it a risk with Rexetin?

Serotonin syndrome is a potentially life-threatening condition associated with medicines that increase serotonin, including Rexetin. Official sources describe this as a reaction that may involve symptoms such as restlessness, a fast heart rate, confusion, and tremors. This condition is primarily a risk when Rexetin is used together with other medicines that also affect serotonin levels.


Q: How long does it typically take to feel the effects of Rexetin?

The onset of the drug's full clinical benefits is generally delayed. Official information indicates that while stable drug levels in the body are reached within one to two weeks, the full effect is described as appearing gradually, often over approximately six weeks of treatment. This delay is due to the gradual biological adaptations that occur in the nervous system.


Q: What is the risk of dependence or addiction with Rexetin?

Rexetin is generally not considered an addictive substance and does not induce euphoria. However, the body may develop a physical dependence on the medication over time. This means that if the medication is stopped abruptly, an individual may experience discontinuation symptoms (often called withdrawal).


Q: Does Rexetin affect my ability to drive or operate machinery?

Official product information advises caution when using Rexetin. Because the medication can cause side effects like drowsiness and dizziness, your ability to drive or safely operate complex machinery may be impaired. Cautionary statements advise that individuals determine how they react to the medication before attempting these tasks.


Q: Is Rexetin a controlled substance?

No, according to regulatory classification in the United States, paroxetine (Rexetin) is not scheduled as a controlled substance. This designation applies to certain medicines with a higher potential for abuse or dependence, which does not include Rexetin.


Q: Can Rexetin affect my blood pressure?

Regulatory sources indicate that Rexetin can affect the heart, potentially causing changes like a faster or irregular heartbeat. While not a primary effect, these changes can affect blood pressure as a secondary consideration. Patients with pre-existing cardiac issues should consult their official product labeling.


Q: Is there a generic version of Rexetin available?

Yes, the active ingredient in Rexetin, which is paroxetine, is available in generic versions. Generic medications contain the same active ingredient and meet the same regulatory standards for quality and effectiveness as the original brand-name drug.


Q: How does Rexetin affect concentration and memory?

Rexetin may have indirect effects on concentration. The medication is associated with Central Nervous System (CNS) side effects such as dizziness, somnolence (drowsiness), and tremors, which can impact focus. Limited research has explored the drug's potential effects on memory in specific study groups.


Q: Is Rexetin known to cause headaches or migraines?

Yes, regulatory documentation lists headaches as a common side effect of Rexetin. In many cases reported in clinical data, this symptom tends to lessen or resolve after the first week of beginning the medication.


Q: Can Rexetin affect my appetite?

Official information notes that Rexetin can cause changes in appetite. Some patients initially report a loss of appetite which may lead to weight loss. However, appetite may return or increase over time, and official documentation also lists weight increase as a common side effect.


Q: Do I need regular blood tests while taking Rexetin?

Routine therapeutic blood monitoring (testing the drug level itself) is generally not indicated for Rexetin. However, blood tests may be relevant for monitoring certain safety concerns, such as hyponatremia (low sodium levels), which is a documented risk, especially in older adults.


Q: Does taking Rexetin affect fertility in men or women?

Official product information states that taking this medication may affect sperm quality and potentially reduce fertility in some men. The official label notes that individuals who are planning to become pregnant should consult with a healthcare professional regarding this information.


Q: How is Rexetin different from benzodiazepines?

Rexetin and benzodiazepines belong to different pharmacological classes. Rexetin is an SSRI (Selective Serotonin Reuptake Inhibitor) that primarily modulates the serotonin system. Benzodiazepines, by contrast, act on the GABA system. Official sources note that Rexetin is not associated with the same high risk of dependence observed with benzodiazepines.


Q: Can Rexetin affect my blood sugar levels?

Regulatory warnings note that for individuals with diabetes, Rexetin can make it more difficult to keep blood sugar levels stable. This may potentially increase the risk of developing hypoglycemia (low blood sugar). The regulatory label notes that frequent monitoring of blood glucose levels may be necessary.


Q: Is Rexetin a type of SSRI or is it a different class?

Yes, the medication Rexetin (paroxetine) is classified in regulatory documents as a Selective Serotonin Reuptake Inhibitor (SSRI). This classification describes how the drug selectively targets the serotonin transporter protein in the nervous system to achieve its intended effect.


Q: Is it true that Rexetin can make anxiety worse initially?

Regulatory information indicates that the drug has been associated with central nervous system (CNS) side effects such as agitation, irritability, and restlessness. These symptoms are sometimes heightened, particularly during the initial few weeks of starting the medication. This temporary increase in activity may be perceived as anxiety.

How should Rexetin be stored and disposed of?

Official Storage Conditions

Rexetin (paroxetine) must be stored at Controlled Room Temperature, specifically between 20 C to 25 C (68 F to 77 F), with excursions permitted up to 30 C. The drug must be protected from light and stored away from excess heat and moisture; authorities advise against storage in the bathroom.

Container and Child Safety

To ensure stability and safety, the medication must be kept in the container it came in, with the lid tightly closed. It must be stored out of the sight and reach of children and secured with the safety cap locked.

Disposal Requirements

Disposal of unused or expired Rexetin should prioritize a drug take-back program. If a take-back option is unavailable, the unused medicine must be mixed with an undesirable substance (e.g., used coffee grounds, dirt) and placed in a sealed bag or container before discarding in the household trash. Personal identifying information must be scratched out from the prescription label before disposal of the empty container.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Rexetin found in:

A-Z Index: